COVID-19 vaccines can prevent corona related hospitalizations, deaths: CDC
USA: Recipients of the SARS-CoV-2 vaccine are at a lower risk of COVID-19-associated hospitalization, post-COVID complications, and death, according to a recent MMWR study.
The study found that Pfizer-BioNTech or Moderna COVID-19 vaccines were 94% effective against COVID-19 hospitalization among fully vaccinated adults and 64% effective among partially vaccinated adults aged ≥65 years.
Prior to this study, clinical trials have suggested high efficacy of the COVID-19 vaccine but there is a need for the evaluation of vaccine effectiveness against several outcomes in real-world settings and in high-risk populations, including older adults.
The study included 417 patients (187 case-patients and 230 controls) median age was 73 years for case-patients and controls, 48% were female. The patients were hospitalized with COVID-19–like illness in 14 states between January and March 2021. Some 45% tested positive for SARS-CoV-2 during their hospital stay (cases); the remainder tested negative (controls).
48% had one or more earlier hospitalizations in the last year, and 4% lived in a long-term care facility before admission. Among the 187 case-patients, 10% had received at least 1 dose of Pfizer-BioNTech or Moderna vaccine ≥14 days before illness onset (including 10% who were partially vaccinated and 0.5% who was fully vaccinated) compared with 27% of 230 test-negative controls (including 19% and 8% who were partially and fully vaccinated, respectively).
Key findings of the study include:
- Prevalence of receipt of Pfizer-BioNTech and Moderna vaccines was similar (53% and 47%, respectively, among those vaccinated with ≥1 doses).
- Adjusted VE for full vaccination using Pfizer-BioNTech or Moderna vaccine was 94%, and adjusted VE for partial vaccination was 64%.
- There was no significant effect for receiving the first dose of a 2-dose COVID-19 vaccine series within 14 days before illness onset (adjusted VE = 3%).
"The findings suggest that SARS-CoV-2 vaccines can reduce the risk for COVID-19–associated hospitalization and, as a consequence of preventing severe COVID-19, vaccination might have an impact on post-COVID conditions (e.g., "long COVID") and deaths," concluded the authors.
Reference:
"Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years — United States, January–March 2021," published in MMWR.
DOI: https://www.cdc.gov/mmwr/volumes/70/wr/mm7018e1.htm#
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.